{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:46:35Z","timestamp":1772196395797,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.vaccine.2009.08.033","type":"journal-article","created":{"date-parts":[[2009,9,10]],"date-time":"2009-09-10T09:48:00Z","timestamp":1252576080000},"page":"6582-6588","source":"Crossref","is-referenced-by-count":23,"title":["Development of candidate combination vaccine for hepatitis E and hepatitis B: A liposome encapsulation approach"],"prefix":"10.1016","volume":"27","author":[{"given":"Shubham","family":"Shrivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita S.","family":"Lole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha S.","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh S.","family":"Shaligram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidya A.","family":"Arankalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.08.033_bib1","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1086\/586899","article-title":"Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination","volume":"197","author":"Vogt","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.08.033_bib2","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal Hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2009.08.033_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/14760584.7.5.535","article-title":"Hepatitis A vaccines","volume":"7","author":"Nothdurft","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2009.08.033_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1586\/14760584.3.3.249","article-title":"A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine","volume":"3","author":"Van Damme","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2009.08.033_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1586\/17474124.1.2.239","article-title":"Recombinant hepatitis E virus vaccine: a successful Phase II trial in a disease-endemic region","volume":"1","author":"Krawczynski","year":"2007","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2009.08.033_bib6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa061847","article-title":"Safety and efficacy of a hepatitis E virus vaccine","volume":"356","author":"Shrestha","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2009.08.033_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14760584.8.3.333","article-title":"Development of hepatitis C virus vaccines: challenges and progress","volume":"8","author":"Stoll-Keller","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2009.08.033_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0169-409X(98)00008-8","article-title":"Aluminium compounds as vaccine adjuvants","volume":"32","author":"Gupta","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2009.08.033_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1440-1711.1998.00746.x","article-title":"Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators","volume":"76","author":"Kovarik","year":"1998","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2009.08.033_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O\u2019Hagan","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2009.08.033_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-5793(96)01507-4","article-title":"Liposome mediated DNA vaccination","volume":"402","author":"Gregoriadis","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2009.08.033_bib12","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1016\/S0264-410X(00)00432-1","article-title":"Liposome mediated DNA vaccination: the effect of vesicle composition","volume":"19","author":"Perrie","year":"2001","journal-title":"Vaccine"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2009.08.033_bib13","doi-asserted-by":"crossref","first-page":"B1","DOI":"10.1016\/S0264-410X(02)00514-5","article-title":"A role for liposomes in genetic vaccination","author":"Gregoriadis","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.033_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/10611869808995862","article-title":"The immunological co-adjuvant action of liposomal interleukin-2: the role of mode of localisation of the cytokine and antigen in the vesicles","volume":"5","author":"Gursel","year":"1997","journal-title":"J Drug Target"},{"key":"10.1016\/j.vaccine.2009.08.033_bib15","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.4049\/jimmunol.159.7.3638","article-title":"Intranasal immunization of a DNA vaccine with 1L-12 and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens","volume":"159","author":"Okada","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.08.033_bib16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0264-410X(98)00346-6","article-title":"A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin\/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice","volume":"17","author":"Babai","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.033_bib17","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/S0264-410X(02)00295-5","article-title":"Liposomal immunostimulatory DNA sequence (ISS-ODN) an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines","volume":"20","author":"Joseph","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.033_bib18","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.vaccine.2008.11.097","article-title":"Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes","volume":"27","author":"Arankalle","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.033_bib19","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1016\/j.vaccine.2007.03.040","article-title":"Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice","volume":"25","author":"Deshmukh","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.033_bib20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/meth.1999.0841","article-title":"Vaccine entrapment in liposomes","volume":"19","author":"Gregoriadis","year":"1999","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2009.08.033_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2893.2006.00801.x","article-title":"Evaluation of human (genotype 1) and swine (genotype 4)-ORF-2 based ELISAs for anti-HEV IgM and IgG detection in an endemic country and search for type 4 human HEV infections","volume":"14","author":"Arankalle","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.vaccine.2009.08.033_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000214862","article-title":"Viral load, antibody titers and recombinant open reading frame 2 protein-induced Th1\/Th2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis E","volume":"52","author":"Saravanabalaji","year":"2009","journal-title":"Intervirology"},{"key":"10.1016\/j.vaccine.2009.08.033_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/314578","article-title":"What level of hepatitis B antibody is protective?","volume":"179","author":"Jack","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.08.033_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/08982100600880432","article-title":"The co-delivery approach to liposomal vaccines: application to the development of influenza A and hepatitis B vaccine candidates","volume":"16","author":"Laing","year":"2006","journal-title":"J Liposome Res"},{"key":"10.1016\/j.vaccine.2009.08.033_bib25","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0264-410X(98)00383-1","article-title":"Immunoadjuvant action of plasmid DNA in liposomes","volume":"17","author":"Gursel","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.033_bib26","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1099\/vir.0.79896-0","article-title":"Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes","volume":"85","author":"Jiao","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.08.033_bib27","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1099\/vir.0.18676-0","article-title":"T helper responses to Japanese encephalitis virus infection are dependent on the route of inoculation and the strain of mouse used","volume":"84","author":"Ramakrishna","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.08.033_bib28","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.iy.12.040194.003223","article-title":"Acquisition of lymphokine producing phenotype by CD4+ T cells","volume":"12","author":"Seder","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2009.08.033_bib29","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.4049\/jimmunol.161.10.5564","article-title":"Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFNg secreting T cells after DNA based immunization","volume":"161","author":"Mancini","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.08.033_bib30","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.4049\/jimmunol.160.3.1320","article-title":"Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes","volume":"160","author":"Chow","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.08.033_bib31","first-page":"1","article-title":"Protection against viral hepatitis: recommendations of the Immunization Practises Advisory Committee (ACIP)","volume":"39","author":"Centers for Disease Control","year":"1990","journal-title":"MMWR Recomm Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09012080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09012080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T17:29:04Z","timestamp":1685122144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09012080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":31,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0264410X09012080"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.08.033","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}